Table 2. Patient demographics and hemophilia characteristics.

Patient No.	Sex/Age (yr)	Diagnosis	Severity	Factor level (%)	Inhibitor	Inhibitor titer (BU)	Clotting factor product	Maintenance therapy
Patient 1	M/19	Hemophilia A	Moderate	1.7	Negative	-	Adynovate	2,000 U every 2-3 days
Patient 2	M/55	Hemophilia A	Mild	10.0	Negative	-	GreenGene F	PRN
Patient 3	M/18	Hemophilia B	Mild	10.0	Negative	-	Rixubis	4,000 U, 7×/4 weeks
Patient 4	M/18	Hemophilia A	Unknown1	Unknown1	Negative	-	Adynovate	PRN (procedure only)
Patient 5	M/18	Hemophilia A	Severe	0.7	Negative	-	Adynovate	2,000 U, 2×/week
Patient 6	M/36	Hemophilia A	Severe	0.5	Negative	-	Afstyla	1,500-2,000 U, 2-3×/week
Patient 7	M/14	Hemophilia A	Mild	10.0	Negative	-	Advate	PRN (procedure only)
Patient 8	M/34	Hemophilia A	Severe	0.2	Negative	-	Advate	2,250 U, 1-2×/week
Patient 9	M/70	Hemophilia A	Moderate	1.7	Negative2	-	Advate	PRN; Advate 4,000 U
Patient 10	M/70	Hemophilia A	Severe	0.7	Positive	5.88	FEIBA	PRN (inhibitor patient)
Patient 11	M/20	Hemophilia B	Severe	0.3	Negative	-	BeneFIX	9,000 U, 1×/week
Patient 12	M/45	Hemophilia A	Severe	0.3	Negative	-	Green Mono	1,000-1,250 U, 3×/week
Patient 13	M/32	Hemophilia A	Severe	0.2	Negative	-	Advate	2,500 U, 1-2×/week

(M: male, BU: Bethesda units, PRN: pro re nata [as needed], -: not available)

¹Patient 4: factor level not documented in available records.

²Patient 9: transient inhibitor in 2019 (0.82 BU); confirmed negative on repeated testing November 2019 to August 2023; Advate used at time of surgery.

Age is at the first surgical case.